Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

Affiliations

¹ Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China.
² Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, China.
³ Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China.
⁴ Department of Anesthesiology, Wuxi Third People's Hospital, Wuxi, Jiangsu 214000, China.
⁵ Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

^# Contributed equally.

Published Erratum

Fei Shi et al. Oncotarget. 2018.

. 2018 Mar 30;9(24):17255.

doi: 10.18632/oncotarget.25063.

¹ Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China.
² Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, China.
³ Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China.
⁴ Department of Anesthesiology, Wuxi Third People's Hospital, Wuxi, Jiangsu 214000, China.
⁵ Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.23091.].

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo.
Shi F, Zhang J, Liu H, Wu L, Jiang H, Wu Q, Liu T, Lou M, Wu H. Shi F, et al. Oncotarget. 2017 Dec 9;9(1):706-717. doi: 10.18632/oncotarget.23091. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416647 Free PMC article.